Nurix Therapeutics (NRIX) put its oncology pipeline in focus at the AACR 2026 Annual Meeting, releasing new preclinical data on its pan mutant BRAF, CBL B, and Aurora Kinase A degrader programs.

Nurix’s latest AACR data drop comes after a mixed share price run, with a 14.75% 1 month share price return but a 1 year to date share price decline of 8.25%, while the 1 year total shareholder return sits at 43.84%, hinting at shifting expectations around both growth potential and risk.

If you are watching how oncology names react to clinical updates, it can also be useful to see what else is moving in early stage biotech. You can start with 34 healthcare AI stocks

With Nurix trading at US$16.57 against an average analyst target of US$30.24, recent AACR buzz and a 44% one-year total return raise the key question: is there still a buying opportunity here, or is future growth already priced in?

Preferred Price-to-Sales Multiple of 23.9x: Is It Justified?

On a P/S basis, Nurix is priced at 23.9x revenue, which is high in absolute terms and sits at the expensive end of the biotech spectrum, even with the stock at $16.57.

The P/S ratio compares a company’s market value with its revenue, which can be useful for loss making biotechs where earnings are not yet a guide. For Nurix, this means investors are currently placing a relatively rich value on each dollar of the $71.8 million in revenue, likely reflecting expectations around its oncology and inflammation pipeline rather than current profitability.

Compared with the US Biotechs industry average P/S of 11.5x, Nurix’s 23.9x stands at more than double, suggesting the market is pricing in stronger revenue potential than a typical peer. However, against a peer group average of 27.5x, the same 23.9x multiple looks more restrained and indicates the stock is not the most aggressively valued name within its closer comparison set. When set against an estimated fair P/S ratio of just 0.1x, the current market valuation looks extremely stretched relative to that modelled level, implying a very sharp reset would be required to line up with that fair ratio.

Result: Price-to-Sales of 23.9x (OVERVALUED)

However, you also need to factor in clinical trial setbacks or partnership changes with Gilead, Sanofi, or Pfizer, which could quickly challenge current revenue and valuation expectations.

Next Steps

Mixed messages on price and valuation can be confusing, so it helps to quickly review the full picture and decide where you stand, including how the balance of upside and downside lines up with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, it pays to widen your search and review fresh opportunities before the market prices them in.

• Spot potential turnaround stories early by scanning through 27 elite penny stocks with strong financials that already show stronger balance sheets and improving financial quality.
• Zero in on quality at a discount by using the 54 high quality undervalued stocks to find companies with solid fundamentals that the market may be overlooking.
• Dial up resilience in your holdings by reviewing the 74 resilient stocks with low risk scores and seeing which names carry lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.